Active — Not RecruitingNot Applicable

Surveys, Blood Testing, and Fibroscan in Screening for Liver Fibrosis and Liver Cirrhosis

United States1,000 participantsStarted 2020-12-22

Plain-language summary

This clinical trial studies the use of surveys, blood testing, and fibroscan in screening for liver fibrosis and liver cirrhosis in new or existing patients of the HOPE clinic seeking usual clinical care. Fibroscan is an imaging procedure of the liver which uses a probe like an ultrasound. Information gathered from this study may help researchers learn more about how to prevent or find liver cancer in patients who are currently receiving care at the HOPE clinic. Early detection of liver cancer may improve survival.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Must be at least 18 years old * Must be a new or existing patient of the HOPE clinic seeking usual clinical care * Must be able to speak and read English or a language other than English for which there is a translator available on site at the HOPE clinic Exclusion Criteria: * Known pregnancy at time of recruitment. The HOPE clinic will ask the female patients if they are pregnant, will ask the participants for their last menstrual period (LMP), and/or they will use the urine pregnancy test (UPT) results in their electronic medical records

What they're measuring

Positive hepatitis B surface antigen test result

Timeframe: At baseline

Trial details

NCT IDNCT04785534

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-08-31

View on ClinicalTrials.gov More Liver and Intrahepatic Bile Duct Carcinoma trials